Hypoxia imaging with 18F-fluoroerythronitroimidazole integrated PET/CT and immunohistochemical studies in non-small cell lung cancer

Clinical Nuclear Medicine

Volumn 38, Issue 8, 2013, Pages 591-596

  Hu, Man ^a   Xing, Ligang ^a   Mu, Dianbin ^a   Yang, Wenfeng ^a   Yang, Guoren ^a   Kong, Li ^a   Yu, Jinming ^a  

^a SHANDONG CANCER HOSPITAL AND INSTITUTE   (China)

Author keywords

FETNIM; hypoxia; immunohistochemistry; non small cell lung cancer; PET CT scans

Indexed keywords

18 F FLUOROERYTHRONITROIMIDAZOLE; CISPLATIN; DOCETAXEL; GEMCITABINE; GLUCOSE TRANSPORTER 1; HYPOXIA INDUCIBLE FACTOR 1ALPHA; MOLECULAR MARKER; NITROIMIDAZOLE DERIVATIVE; UNCLASSIFIED DRUG; VASCULOTROPIN; DIAGNOSTIC AGENT; FLUOROERYTHRONITROIMIDAZOLE; GLUCOSE;

ADJUVANT CHEMOTHERAPY; ADULT; AGED; ANGIOGENESIS; ARTICLE; CALCULATION; CANCER STAGING; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL EVALUATION; COMPUTER ASSISTED EMISSION TOMOGRAPHY; COMPUTER TOMOGRAPHY SCANNER; CORRELATION ANALYSIS; FEMALE; GLUCOSE METABOLISM; HUMAN; HYPOXIA; IMMUNOHISTOCHEMISTRY; LUNG BIOPSY; LUNG NON SMALL CELL CANCER; MALE; MULTIPLE CYCLE TREATMENT; OUTCOME ASSESSMENT; PROSPECTIVE STUDY; PROTEIN EXPRESSION; STATISTICAL ANALYSIS; STATISTICAL SIGNIFICANCE; UPREGULATION; CELL HYPOXIA; CLINICAL TRIAL; COMPUTER ASSISTED TOMOGRAPHY; LUNG TUMOR; METABOLISM; MIDDLE AGED; MULTIMODAL IMAGING; NEOVASCULARIZATION (PATHOLOGY); PATHOLOGY; POSITRON EMISSION TOMOGRAPHY; SURVIVAL; VASCULARIZATION; VERY ELDERLY; CARCINOMA, NON-SMALL-CELL LUNG; DIAGNOSTIC USE; LUNG NEOPLASMS;

ADULT; AGED; AGED, 80 AND OVER; CARCINOMA, NON-SMALL-CELL LUNG; CELL HYPOXIA; FEMALE; GLUCOSE; HUMANS; IMMUNOHISTOCHEMISTRY; LUNG NEOPLASMS; MALE; MIDDLE AGED; MULTIMODAL IMAGING; NEOVASCULARIZATION, PATHOLOGIC; NITROIMIDAZOLES; POSITRON-EMISSION TOMOGRAPHY; SURVIVAL ANALYSIS; TOMOGRAPHY, X-RAY COMPUTED;

EID: 84880733893     PISSN: 03639762     EISSN: 15360229     Source Type: Journal    
DOI: 10.1097/RLU.0b013e318279fd3d     Document Type: Article

References (28)

1. Nordsmark M, Bentzen SM, Rudat V, et al. Prognostic value of tumor oxygenation in 397 head and neck tumors after primary radiation therapy. An international multi-center study. Radiother Oncol. 2005;77:18-24.
2. Le QT, Chen E, Salim A, et al. An evaluation of tumor oxygenation and gene expression in patients with early stage non-small cell lung cancers. Clin Cancer Res. 2006;12:1507-1514.
3. 18F]fluorideoxyglucose positron emission tomography imaging. Clin Cancer Res. 2004;10:2245-2252.
4. 18F]FAZA PET in head and neck cancer patients: a pilot study. Eur J Nucl Med Mol Imaging. 2007;34:1566-1565.
5. 60Cu-ATSM: relationship to therapeutic responseVa preliminary report. Int J Radiat Oncol Biol Phys. 2003;55:1233-1238.
6. Rajendran JG, Schwartz DL, O'Sullivan J, et al. Tumor hypoxia imaging with [F-18] fluoromisonidazole positron emission tomography in head and neck cancer. Clin Cancer Res. 2006;12:5435-5441.
7. 18F] fluordeoxyglucose positron emission tomography in response evaluation after chemo-/radiotherapy of non-small-cell lung cancer: a feasibility study. BMC Cancer. 2006;6:51-58.
8. Yang DJ, Wallace S, Cherif A, et al. Development of F-18-labeled fluoro-erythronitroimidazole as a PET agent for imaging tumor hypoxia. Radiology. 1995;194:795-800.
9. 18F]FETNIM: a potential marker for PET. J Nucl Med. 2001;42:1397-13404.
10. 18F- fluoroerythronitroimidazole radiation dosimetry in cancer studies. J Nucl Med. 2002;43:1674-1680.
11. 18F]FMISO in an experimental mammary carcinoma. Eur J Nucl Med Mol Imaging. 2004;31:513-520.
12. 18F-fluorodeoxyglucose positron emission tomography and prognostic value in locally advanced non-small-cell lung cancer. Clin Lung Cancer. 2010;11: 335-340.
13. Lehtiö K, Eskola O, Viljanen T, et al. Imaging perfusion and hypoxia with PET to predict radiotherapy response in head-and-neck cancer. Int J Radiat Oncol Biol Phys. 2004;59:971-982.
14. 18F-FETNIM PET in esophageal squamous cell carcinoma: a pilot clinical study. Dis Esophagus. 2012;25:54-61.
15. Bachtiary B, Schindl M, Potter R, et al. Overexpression of hypoxia-inducible factor 1a indicates diminished response to radiotherapy and unfavorable prognosis in patients receiving radical radiotherapy for cervical cancer. Clin Cancer Res. 2003;9:2234-2240.
16. Minami K, Saito Y, Imamura H, et al. Prognostic significance of p53, Ki-67, VEGF and Glut-1 in resected stage I adenocarcinoma of the lung. Lung Cancer. 2002;38:51-57.
17. van Baardwijk A, Dooms C, van Suylen RJ, et al. The maximum uptake of (18)F-deoxyglucose on positron emission tomography scan correlates with survival, hypoxia inducible factor-1a and GLUT1 in non-small cell lung cancer. Eur J Cancer. 2007;43:1392-1398.
18. Greene FL, Page DL, Fleming ID, et al. AJCC Cancer Staging Manual. 6th ed. New York, NY: Springer; 2002:165-177.
19. 18F]-fluoro-2-deoxy-D-glucose uptake on positron emission tomography in thymic epithelial tumors. J Clin Oncol. 2010;28:3746-3753.
20. 18F-FDG PET. J Nucl Med. 2006;47:1921-1926.
21. Kaira K, Ohde Y, Okumura T, et al. Relationship between (18)F-FDG uptake on PET and various biologic molecular markers in benign pulmonary lesion: comparison with primary lung cancer. Ann Nucl Med. 2012;26:288.
22. Bos R, van Der Hoeven JJ, van Der Wall E, et al. Biologic correlates of (18)fluorodeoxyglucose uptake in human breast cancer measured by positron emission tomography. J Clin Oncol. 2002;20:379-387.
23. 18F]FETNIM) and PET using tumor-to-plasma ratio. Eur J Nucl Med Mol Imaging. 2003;30:101-108.
24. 60Cu-ATSM in cancer of the uterine cervix. Mol Imaging Biol. 2007;9:278-283.
25. 18F-FDG PET, and immunohistochemical studies. J Nucl Med. 2006;47:410-418.
26. Bos R, Zhong H, Hanrahan CF, et al. Levels of hypoxia-inducible factor-1-alpha during breast carcinogenesis. J Natl Cancer Inst. 2001;93:309-314.
27. Giatromanolaki A, Koukourakis MI, Sivridis E, et al. Relation of hypoxia in-ducible factor 1 alpha and 2 alpha in operable non-small cell lung cancer to angiogenic/molecular profile of tumours and survival. Br J Cancer. 2001;85: 881-890.
28. Zhang H, Zhang Z, Xu Y, et al. The expression of hypoxia induciblefactor 1-alpha in lung cancer and its correlation with P53 and VEGF. J Huazhong Univ Sci Technolog Med Sci. 2004;24:124-127.